0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Notice of Redundant Publication: “Transdermal Rotigotine: Double-blind, Placebo-Controlled Trial in Parkinson Disease” (Arch Neurol. 2007;64[5]:676-682)—Reply

Joseph Jankovic, MD; Ray L. Watts, MD; Wayne Martin, MD; Babak Boroojerdi, MD
Arch Neurol. 2007;64(12):1801. doi:10.1001/archneur.64.12.1801.
Text Size: A A A
Published online

Extract

In reply

We respectfully but strongly disagree with Dr Rosenberg's perception that the 2 cited articles are redundant. We welcome the opportunity to respond to his letter and, in the limited space allowed, explain why the 2 papers are clearly different. While the original article reported the primary efficacy and safety results of the SP 512 Transdermal Rotigotine Phase 3 Pivotal Clinical Trial in Early Parkinson's Disease,1 the second article focused on the secondary outcome variables and plasma pharmacokinetics of rotigotine administered once daily via a novel transdermal delivery system.2 In our recent communications to Dr Rosenberg, we explained that the results of this important study and the many outcome variables along with unique pharmacokinetic data were too extensive to report in a single article submitted to Neurology. Therefore, in the Archives paper,2 we reported primarily data not described in the Neurology paper,1 such as the effects of rotigotine versus placebo on Clinical Global Impression (CGI) scores, percentage of patients considered moderately to markedly ill, Epworth Sleepiness Scale (ESS) scores, quality of life measures (EQ-5D Index and EQ-5D Health Score), plasma concentrations of rotigotine, and prolactin levels in addition to presenting different aspects of the design of the study and the Unified Parkinson's Disease Rating Scale (UPDRS) subscores. The only overlap between the 2 articles is the report of 20% response rate and the adverse events, which were included in response to queries by 1 of the reviewers for Archives. In submitting the 2 separate papers, we intended to report as completely as possible the data generated by the large multicenter study and in the interest of full disclosure. We were, therefore, surprised by the allegations raised in Dr Rosenberg's letter because we never considered the 2 papers duplicative or redundant. Reporting different aspects of clinical trials, such as primary and secondary outcome variables, in separate publications is a common and accepted practice, given the wide range of numerous assessment measures generated by large studies and limitations of space imposed by various scientific journals. We are reassured that an independent review by other academic neurologists came to the same conclusion that the 2 papers were clearly different in intent and content.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

127 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Parkinsonism

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Make the Diagnosis: Parkinsonism

brightcove.createExperiences();